Are semaglutide and tirzepatide still in shortage in 2025?

As of January 2025, the FDA has declared that tirzepatide shortages have ended, while semaglutide shortages are resolving. Brand-name products are now more widely available, though some strengths may still experience intermittent supply issues.

Can I still get compounded semaglutide or tirzepatide?

The availability of compounded versions is changing. With tirzepatide off the shortage list, compounding may be restricted. Semaglutide compounding availability depends on ongoing shortage status. Patients should consult with healthcare providers about their specific access options.

What happens to my current prescription if shortages end?

Patients on compounded medications may need to transition to FDA-approved brand-name products as shortages resolve. Your healthcare provider will work with you to ensure continuity of care and determine the best transition plan.

Will prices change after shortages end?

Brand-name medications typically cost more than compounded versions. However, increased supply may lead to more competitive pricing and better insurance coverage. Patient assistance programs may also become more accessible.

Semaglutide and Tirzepatide in 2025: End of Shortages and What It Means

Shortage Timeline & Current Status

The journey of GLP-1 medication shortages has been a defining challenge for patients and healthcare providers. Understanding the timeline helps contextualize the current situation and what to expect moving forward.

Historical Shortage Timeline

Key Milestones

2022: Initial shortages begin as demand outpaces supply
2023: Shortages intensify; FDA adds medications to official shortage list
Mid-2024: Manufacturers ramp up production capacity
October 2024: FDA removes tirzepatide from shortage list
January 2025: Semaglutide supply approaching normal levels

Current Availability by Medication

2025 Availability Status

Feature	Semaglutide	Tirzepatide
FDA Shortage Status	Resolving	Ended
Brand Name Availability	Good	Excellent
Most Doses Available
Compounding Status	Permitted	Restricted
Expected Wait Times	Minimal	None

Learn more about how to access semaglutide and tirzepatide options in the current market.

FDA Actions & Manufacturer Updates

The FDA's decision to remove tirzepatide from the shortage list reflects significant improvements in manufacturing capacity and supply chain management.

Manufacturer Production Increases

Key Production Improvements

Eli Lilly (Mounjaro/Zepbound): Invested billions in new manufacturing facilities; expanded production by 150% from 2023 to 2024
Novo Nordisk (Ozempic/Wegovy): Added new production lines; increased output capacity by 100%
Supply Chain Optimization: Improved logistics and distribution networks to reduce delivery delays

Compounded Medication Access

The changing shortage status has significant implications for patients currently using compounded versions of these medications.

Compounded vs Brand-Name Access

Feature	Before Shortage End	After Shortage End
Compounded Access	Widely Available	Restricted/Limited
Brand Name Access	Limited	Readily Available
Cost (Average)	$200-400/month	$900-1,400/month
Insurance Coverage	Rare	Improving
Quality Oversight	Varies	FDA Regulated

For more information on compounded options, read our guide on compounded semaglutide safety and cost comparisons.

What Patients Should Do Now

If you're currently taking or considering GLP-1 medications, here's your action plan for navigating the changing landscape.

Immediate Action Steps

Contact Your Provider: Discuss transition options and timing before your current supply runs out
Review Insurance Coverage: Check if your insurance now covers brand-name GLP-1 medications for weight loss
Explore Patient Assistance: Research manufacturer savings programs (may reduce costs by $500+ monthly)
Plan for Cost Changes: Budget for potential increase in medication expenses
Document Your Progress: Keep records of your weight loss and health improvements to support insurance authorization

The Bottom Line

The resolution of GLP-1 medication shortages marks a significant milestone in weight management treatment. While the end of shortages brings challenges—particularly around cost and access to compounded medications—it also ensures better medication quality, consistency, and long-term availability.

Stay informed about the latest developments in GLP-1 medications by reading our Complete GLP-1 Guide and comparing your options with Tirzepatide vs Semaglutide.

Scientific References

FDA Drug Shortages Database (2025). Current Drug Shortages. U.S. Food and Drug Administration.Read Study
Eli Lilly and Company (2024). Manufacturing and Supply Update. Corporate Communications.Read Study
Novo Nordisk (2024). Supply and Production Expansion Announcement. Investor Relations.Read Study